The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Staphylococcal Biofilms: Challenges and Novel Therapeutic Perspectives
Open accessAbstract
Staphylococci, like Staphylococcus aureus and S. epidermidis, are common colonizers of the human microbiota. While being harmless in many cases, many virulence factors result in them being opportunistic pathogens and one of the major causes of hospital-acquired infections worldwide. One of these virulence factors is the ability to form biofilms—three-dimensional communities of microorganisms embedded in an extracellular polymeric matrix (EPS). The EPS is composed of polysaccharides, proteins and extracellular DNA, and is finely regulated in response to environmental conditions. This structured environment protects the embedded bacteria from the human immune system and decreases their susceptibility to antimicrobials, making infections caused by staphylococci particularly difficult to treat. With the rise of antibiotic-resistant staphylococci, together with difficulty in removing biofilms, there is a great need for new treatment strategies. The purpose of this review is to provide an overview of our current knowledge of the stages of biofilm development and what difficulties may arise when trying to eradicate staphylococcal biofilms. Furthermore, we look into promising targets and therapeutic methods, including bacteriocins and phage-derived antibiofilm approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacterial Biofilms: A Common Cause of Persistent Infections
Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999) · Science · doi:10.1126/science.284.5418.1318 · Cited by 12,167
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Antimicrobial resistance: a global multifaceted phenomenon
Prestinaci, F., Pezzotti, P., & Pantosti, A. (2015) · Pathogens and Global Health · doi:10.1179/2047773215y.0000000030 · Cited by 3,296
Waves of resistance: Staphylococcus aureus in the antibiotic era
Chambers, H. F., & DeLeo, F. R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2200 · Cited by 2,718
Bacteriocins of gram-positive bacteria
Jack, R. W., Tagg, J. R., & Ray, B. (1995) · Microbiological Reviews · doi:10.1128/mr.59.2.171-200.1995 · Cited by 2,711
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.34 · Cited by 1,612
James, G. A., Swogger, E., Wolcott, R., Pulcini, E. D., Secor, P., Sestrich, J., Costerton, J. W., & Stewart, P. S. (2008) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2007.00321.x · Cited by 1,543 · cited 1×
“In addition, staphylococcal biofilm-associated infections with a polymicrobial nature involve several body districts; most notably, these include cystic fibrosis lung and diabetic foot infections [39,40].”
BackgroundInfection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025025 · Cited by 1,095
Candida albicans Biofilms and Human Disease
Nobile, C. J., & Johnson, A. D. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104330 · Cited by 1,057
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials
Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A., & Marraffini, L. A. (2014) · Nature Biotechnology · doi:10.1038/nbt.3043 · Cited by 986
Biofilm Dispersal: Mechanisms, Clinical Implications, and Potential Therapeutic Uses
Kaplan, J. B. (2010) · Journal of Dental Research · doi:10.1177/0022034509359403 · Cited by 949
Heilmann, C., Hussain, M., Peters, G., & Götz, F. (1997) · Molecular Microbiology · doi:10.1046/j.1365-2958.1997.4101774.x · Cited by 700 · cited 3×
“epidermidis [54], and was later confirmed to be present in other Staphylococcus species as well [65].”
BackgroundIzano, E. A., Amarante, M. A., Kher, W. B., & Kaplan, J. B. (2008) · Applied and Environmental Microbiology · doi:10.1128/aem.02073-07 · Cited by 553
LYSOSTAPHIN: A NEW BACTERIOLYTIC AGENT FOR THE STAPHYLOCOCCUS
Schindler, C. A., & Schuhardt, V. T. (1964) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.51.3.414 · Cited by 482
Hassan, M., Kjos, M., Nes, I. F., Diep, D. B., & Lotfipour, F. (2012) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2012.05338.x · Cited by 402
Self-citation
Cited by
Tolerance and resistance of microbial biofilms
Ciofu, O., Moser, C., Jensen, P. Ø., & Høiby, N. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00682-4 · Cited by 1,124
Understanding bacterial biofilms: From definition to treatment strategies
Zhao, A., Sun, J., & Liu, Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1137947 · Cited by 743
Skeletal infections: microbial pathogenesis, immunity and clinical management
Masters, E. A., Ricciardi, B. F., Bentley, K. L. D. M., Moriarty, T. F., Schwarz, E. M., & Muthukrishnan, G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00686-0 · Cited by 735
Metadata
- Authors
- Kranjec, C., Morales Angeles, D., Torrissen Mårli, M., Fernández, L., García, P., Kjos, M., & Diep, D. B.
- Venue
- Antibiotics
- Publisher
- MDPI AG
- Published
- 2021-01-29
- Volume
- 10
- Issue
- 2
- Pages
- 131
- ISSN
- 2079-6382 (ISSN-L)
- OpenAlex
- W3126956654
- Cited by
- 168
- References
- 16
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.